GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioLargo Inc (OTCPK:BLGO) » Definitions » ROE %

BioLargo (BioLargo) ROE % : -41.92% (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is BioLargo ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BioLargo's annualized net income for the quarter that ended in Dec. 2023 was $-2.92 Mil. BioLargo's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $6.96 Mil. Therefore, BioLargo's annualized ROE % for the quarter that ended in Dec. 2023 was -41.92%.

The historical rank and industry rank for BioLargo's ROE % or its related term are showing as below:

BLGO' s ROE % Range Over the Past 10 Years
Min: -989.09   Med: -130.12   Max: -53.83
Current: -53.83

During the past 13 years, BioLargo's highest ROE % was -53.83%. The lowest was -989.09%. And the median was -130.12%.

BLGO's ROE % is ranked worse than
96.35% of 1535 companies
in the Chemicals industry
Industry Median: 5.26 vs BLGO: -53.83

BioLargo ROE % Historical Data

The historical data trend for BioLargo's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLargo ROE % Chart

BioLargo Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -989.09 -166.37 -93.86 -59.79

BioLargo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.52 -17.54 -77.25 -66.50 -41.92

Competitive Comparison of BioLargo's ROE %

For the Chemicals subindustry, BioLargo's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLargo's ROE % Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioLargo's ROE % distribution charts can be found below:

* The bar in red indicates where BioLargo's ROE % falls into.



BioLargo ROE % Calculation

BioLargo's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-3.504/( (4.878+6.844)/ 2 )
=-3.504/5.861
=-59.79 %

BioLargo's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-2.916/( (7.069+6.844)/ 2 )
=-2.916/6.9565
=-41.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


BioLargo  (OTCPK:BLGO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.916/6.9565
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.916 / 17.48)*(17.48 / 7.375)*(7.375 / 6.9565)
=Net Margin %*Asset Turnover*Equity Multiplier
=-16.68 %*2.3702*1.0602
=ROA %*Equity Multiplier
=-39.53 %*1.0602
=-41.92 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.916/6.9565
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.916 / -4.08) * (-4.08 / -2.428) * (-2.428 / 17.48) * (17.48 / 7.375) * (7.375 / 6.9565)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7147 * 1.6804 * -13.89 % * 2.3702 * 1.0602
=-41.92 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


BioLargo ROE % Related Terms

Thank you for viewing the detailed overview of BioLargo's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLargo (BioLargo) Business Description

Traded in Other Exchanges
N/A
Address
14921 Chestnut Street, Westminster, CA, USA, 92683
BioLargo Inc invents, develops, and commercializes platform technologies to solve challenging environmental problems like PFAS contamination, advanced water, and wastewater treatment, industrial odor, and VOC control, air quality control, and infection control. The company holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. BioLargo invents or acquires novel technologies and develops them to maturity through its operating subsidiaries. It monetizes through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation, and/or the sale of the IP. The firm's technologies are commercially available and are advancing as disrupters in their respective markets.
Executives
Linda Park director 14921 CHESTNUT STREET, WESTMINSTER CA 92683
Christina Elaine Bray director PO BOX 234, FREDERICK CO 80530
Jack B. Strommen director 7108 31ST AVENUE N., MINNEAPOLIS MN 55427
Roberts Kent Charles Ii director 1146 OXFORD ROAD, SAN MARINO CA 91108
John S. Runyan director 30001 HILLSIDE TERRACE, SAN JUAN CAPISTRANO CA 92675
Dennis E Marshall director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Dennis P Calvert director, 10 percent owner, officer: Chief Executive Officer 3500 GARRY AVE, SANTA ANA CA 92704
New Millennium Capital Partners, Llc 10 percent owner 16333 PHOEBE AVENUE, LA MIRADA CA 90638
Charles K Dargan officer: Chief Financial Officer 8055 W. MANCHESTER AVE., SUITE 405, PLAYA DEL REY CA 90293
Joseph L Provenzano director, officer: Corporate Secretary 3500 W. GARRY AVENUE, SANTA ANA CA 92704
Iowc Technologies, Inc. 10 percent owner 2603 MAIN STREET, SUITE 1155, IRVINE CA 92614
Kenneth Reay Code 10 percent owner 16150 HERON AVENUE, LA MIRADA CA 90638
Gary Adrian Cox director 3500 W. GARRY AVENUE, SANTA ANA CA 92705
Steven V Harrison director
Eduardo Ruiz director, 10 percent owner